177Lu-PSMA-I&T联合镭-223治疗转移性去势抵抗性前列腺癌:AlphaBet试验中期分析
AlphaBet是一项研究者发起的单中心单臂1/2期试验,评估177Lu-PSMA-I&T联合镭-223在转移性去势抵抗性前列腺癌患者中的安全性和初步抗肿瘤活性。37例患者入组,36例安全性分析,33例活性分析。18例(55%;95% CI 36-72)患者PSA下降≥50%,5例(14%)发生≥3级治疗相关不良事件,无治疗相关死亡。
要点
- PSA缓解率(下降≥50%)为55%(95% CI 36-72),≥3级治疗相关不良事件发生率14%。
- 常见≥3级不良事件为贫血(11%)和中性粒细胞减少(8%),无治疗相关死亡。
核心结论
- 177Lu-PSMA-I&T联合镭-223在转移性去势抵抗性前列腺癌骨转移患者中安全可行。
- 研究结果支持进一步评估α发射体和β发射体联合治疗策略。
研究设计与样本
- 研究者发起的单中心单臂1/2期试验(AlphaBet),在澳大利亚墨尔本Peter MacCallum癌症中心开展。
- 入组37例进展性转移性去势抵抗性前列腺癌成人患者(≥18岁),ECOG评分0-2,至少两处未放疗骨转移,既往接受过雄激素受体通路抑制剂,PSMA阳性(最大标准化摄取值≥20),无不一致病灶。
- 主要终点:1期为最大耐受或给药剂量及推荐2期剂量;2期为PSA缓解率,在最大耐受或给药剂量治疗的所有患者中分析。
- 安全性分析纳入所有接受至少一剂方案治疗的患者;本次为2024年5月30日方案修订后增加的中期分析。
主要发现
- 18例(55%;95% CI 36-72)患者PSA下降≥50%。
关键数值与推荐
- PSA缓解率(下降≥50%):55%(95% CI 36-72),33例可评估患者中18例。
- ≥3级治疗相关不良事件:14%(36例中5例),包括贫血11%(4例)和中性粒细胞减少8%(3例)。
临床怎么用
- 对于PSMA阳性、伴骨转移的转移性去势抵抗性前列腺癌患者,可考虑177Lu-PSMA-I&T联合镭-223方案,但需关注血液学毒性。
- 治疗期间应监测血常规,尤其贫血和中性粒细胞减少;约半数患者可能因疾病进展或不良事件提前终止治疗。
局限性
- 单中心、单臂设计,样本量有限,结果需进一步随机对照试验验证。
- 本次为中期分析,随访时间尚短,生存终点数据不成熟。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies for patients with metastatic castration-resistant prostate cancer; however, resistance and progression are inevitable. We aimed to evaluate the safety and preliminary antitumour activity of 177Lu-PSMA-I&T combined with 223Ra in this patient group. METHODS: We conducted an investigator-initiated, single-centre, single-arm, phase 1/2 trial (AlphaBet) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Adults (aged ≥18 years) with a diagnosis of progressive, metastatic castration-resistant prostate cancer, an Eastern Cooperative Oncology Group performance status score of 0-2, at least two visible bone metastases not treated with radiotherapy, previous exposure to an androgen receptor pathway inhibitor, prostate-specific membrane antigen (PSMA)-positive disease (defined by maximum standardised uptake value ≥20 at a site of disease), and no discordant sites (ie, avid on 2-[18F]fluoro-2-deoxy-D-glucose-PET-CT with minimal PSMA expression and no uptake on bone scintigraphy) were eligible for inclusion. Phase 1 dose-escalation assessed two dose levels of 223Ra (27·5 kBq/kg and 55·0 kBq/kg) combined with 7·4 GBq 177Lu-PSMA-I&T, administered intravenously every 6 weeks for up to six cycles. Phase 2 dose expansion continued with the recommended phase 2 dose. Co-primary endpoints were the maximum tolerated or administered dose and the recommended phase 2 dose (phase 1), and the PSA response rate (phase 2), analysed in all patients treated at the maximum tolerated or administered dose in either phase. Safety was assessed in all patients who received at least one dose of either protocol treatment in phase 1 or 2. Herein, we report the results of an interim analysis, which was added to the protocol following an amendment on May 30, 2024. This trial is registered at ClinicalTrials.gov (NCT05383079) and follow-up is ongoing. FINDINGS: Between Nov 3, 2022, and Nov 5, 2024, 37 patients were enrolled, of whom 36 (97%; median age 72·5 years [IQR 67·0-78·0]) were included in the safety analysis and 33 (89%) were included in the preliminary activity analysis. No dose-limiting toxicities were observed. The recommended phase 2 dose of 223Ra was 55·0 KBq/kg combined with 7·4 GBq 177Lu-PSMA-I&T, administered every 6 weeks. With a median follow-up of 13·3 months (IQR 8·7-17·1), 11 (31%) patients completed all six cycles of both treatments. 18 (50%) patients discontinued treatment early, primarily due to unequivocal disease progression (11 [61%]) or adverse events (three [17%]). A reduction in PSA of at least 50% was observed in 18 (55%; 95% CI 36-72) patients. Grade 3 or higher treatment-related adverse events occurred in five (14%) of 36 patients, including anaemia (four [11%]) and neutropenia (three [8%]), with no treatment-related deaths. Non-clinically significant grade 3 lymphopenia occurred in ten (28%) patients. INTERPRETATION: The combination of 177Lu-PSMA-I&T and 223Ra is safe and feasible in patients with metastatic castration-resistant prostate cancer and bone metastases. These findings warrant further evaluation of combined α-emitting and β-emitting approaches. FUNDING: Prostate Cancer Foundation, Bayer, and National Health and Medical Research Council.
引用
- Kostos L, Buteau JP, Xie J, et al. Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial. Lancet Oncol. 2025. PMID: 41119954. doi:10.1016/S1470-2045(25)00559-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。